Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

84.43USD
1:01pm EDT
Change (% chg)

$-0.93 (-1.08%)
Prev Close
$85.36
Open
$85.91
Day's High
$86.50
Day's Low
$84.33
Volume
1,162,478
Avg. Vol
3,197,677
52-wk High
$86.50
52-wk Low
$59.81

Latest Key Developments (Source: Significant Developments)

Merck CEO Frazier:less appetite for big deals than mid or small-sized deals
11:44am EDT 

June 20 (Reuters) - Merck & Co Inc ::CEO Frazier says the company has less appetite for big deals than mid or small-sized deals-investor day.CEO Frazier says most big pharma deals have not created the value they said they were going to create.  Full Article

Merck Prepares For CEO's Departure With Internal Successor Hunt - Bloomberg
Wednesday, 19 Jun 2019 12:38pm EDT 

June 19 (Reuters) - :MERCK PREPARES FOR CEO'S DEPARTURE WITH INTERNAL SUCCESSOR HUNT - BLOOMBERG.  Full Article

Astrazeneca And Merck's Lynparza Approved In Japan
Wednesday, 19 Jun 2019 06:45am EDT 

June 19 (Reuters) - Merck & Co Inc ::ASTRAZENECA AND MERCK’S LYNPARZA® (OLAPARIB) APPROVED IN JAPAN AS FIRST-LINE MAINTENANCE THERAPY IN PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER.MERCK & CO - JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA) HAS APPROVED LYNPARZA AS A MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY.MERCK & CO INC - LYNPARZA APPROVAL IN JAPAN WAS BASED ON DATA FROM RANDOMIZED, DOUBLE-BLINDED PHASE 3 SOLO-1 TRIAL.  Full Article

FDA Approves Merck's Keytruda As Monotherapy For Patients With Metastatic Small Cell Lung Cancer
Tuesday, 18 Jun 2019 06:45am EDT 

June 18 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY FOR PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY AND AT LEAST ONE OTHER PRIOR LINE OF THERAPY.MERCK & CO INC - CONTINUED APPROVAL FOR INDICATION MAY BE CONTINGENT UPON VERIFICATION AND DESCRIPTION OF CLINICAL BENEFIT IN CONFIRMATORY TRIALS..MERCK & CO INC - DECISION MARKS FIRST INDICATION FOR KEYTRUDA IN SCLC..  Full Article

IBM, KPMG, Merck And Walmart in blockchain collaboration with FDA
Thursday, 13 Jun 2019 08:05am EDT 

June 13 (Reuters) - Walmart Inc ::IBM, KPMG, MERCK AND WALMART TO COLLABORATE AS PART OF FDA'S PROGRAM TO EVALUATE THE USE OF BLOCKCHAIN TO PROTECT PHARMACEUTICAL PRODUCT INTEGRITY.IBM - PILOT PROJECT IS SCHEDULED TO BE COMPLETED IN Q4 OF 2019.IBM - BLOCKCHAIN MAY BE INTEGRATED WITH EXISTING SUPPLY CHAIN AND TRACEABILITY SYSTEMS.IBM - PROGRAM IS TO ASSIST DRUG SUPPLY CHAIN STAKEHOLDERS IN DEVELOPING A SYSTEM THAT WILL IDENTIFY, TRACE CERTAIN PRESCRIPTION DRUGS DISTRIBUTED IN U.S..  Full Article

Merck Says Keytruda Showed Improved Overall Survival In Head & Neck Cancer Trial
Friday, 31 May 2019 06:45am EDT 

May 31 (Reuters) - Merck & Co Inc ::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DEMONSTRATES IMPROVED OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AT FINAL ANALYSIS OF PIVOTAL PHASE 3 KEYNOTE-048 TRIAL.MERCK & CO - FOR DUAL PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL, STATISTICAL SIGNIFICANCE NOT ACHIEVED FOR KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY IN CPS≥20 POPULATION VERSUS EXTREME REGIMEN.MERCK & CO - FOR CPS ≥1 POPULATION KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 35% IN THESE PATIENTS, WITH SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.MERCK & CO - KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 40% IN PATIENTS WHOSE TUMORS EXPRESSED PD-L1 WITH CPS≥20, SHOWING SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.  Full Article

Zymeworks Earns Milestone Payment In Merck Collaboration
Wednesday, 29 May 2019 06:45am EDT 

May 29 (Reuters) - Zymeworks Inc ::ZYMEWORKS EARNS MILESTONE PAYMENT IN MERCK COLLABORATION.ZYMEWORKS - UNDER TERMS, CO GRANTED MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, DEVELOP & COMMERCIALIZE CERTAIN BISPECIFIC THERAPEUTIC CANDIDATES.ZYMEWORKS - UNDER TERMS, CO IS ELIGIBLE TO RECEIVE ADDITIONAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON PRODUCT SALES.ZYMEWORKS INC - WILL RECEIVE US$2.0 MILLION IN CONNECTION WITH MERCK'S COMPLETION OF A LATE-STAGE PRECLINICAL STUDY FOR A BISPECIFIC ANTIBODY CANDIDATE.  Full Article

Merck Sets Quarterly Dividend Of $0.55 Per Share
Tuesday, 28 May 2019 04:05pm EDT 

May 28 (Reuters) - Merck & Co Inc ::SETS QUARTERLY DIVIDEND OF $0.55PER SHARE.  Full Article

Merck To Acquire Peloton Therapeutics For An Upfront Payment Of $1.05 Billion In Cash
Tuesday, 21 May 2019 06:45am EDT 

May 21 (Reuters) - Merck & Co Inc ::MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK & CO INC - MERCK, THROUGH A SUBSIDIARY, WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH.MERCK & CO INC - WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH..MERCK & CO - PELOTON SHAREHOLDERS ELIGIBLE TO RECEIVE FURTHER $1.15 BILLION CONTINGENT UPON SUCCESSFUL ACHIEVEMENT OF FUTURE MILESTONES FOR CERTAIN CANDIDATES.MERCK & CO INC - ACQUISITION INCLUDES NOVEL LATE-STAGE RENAL CELL CARCINOMA CANDIDATE, PT2977.MERCK & CO INC - COMPANIES ANTICIPATE ACQUISITION WILL CLOSE IN Q3 OF 2019.  Full Article

Third Point LLC Dissolves Share Stake In Merck & Co Inc
Wednesday, 15 May 2019 05:20pm EDT 

May 15 (Reuters) - Third Point LLC::THIRD POINT LLC DISSOLVES SHARE STAKE IN MERCK & CO INC.THIRD POINT LLC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Walmart, Merck in blockchain collaboration with FDA

June 13 IBM Corp, Merck & Co, KPMG and Walmart Inc said on Thursday they will be a part of U.S. Food and Drug Administration's pilot program that will explore using blockchain to identify, track and trace prescription drugs.